Immunosuppression for interstitial lung disease in systemic sclerosis
S Cappelli, S Guiducci, SB Randone… - European Respiratory …, 2013 - Eur Respiratory Soc
The efficacy of immunosuppressors in the treatment of systemic sclerosis-interstitial lung
disease is still matter of controversy. In this review we will analyse the evidence that …
disease is still matter of controversy. In this review we will analyse the evidence that …
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
M Iudici, G Moroncini, P Cipriani, R Giacomelli… - Autoimmunity …, 2015 - Elsevier
Interstitial lung disease (ILD) affects about 90% of patients with systemic sclerosis (SSc). It is
associated with a restrictive lung disease in only 30% of patients and is progressive in an …
associated with a restrictive lung disease in only 30% of patients and is progressive in an …
Interstitial lung disease in systemic sclerosis
G Bussone, L Mouthon - Autoimmunity reviews, 2011 - Elsevier
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and
mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies …
mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies …
Interstitial lung disease in systemic sclerosis
EA Renzoni - Monaldi Archives for Chest Disease, 2007 - monaldi-archives.org
Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis of the skin
and internal organs, autoimmune abnormalities and widespread vasculopathy. A degree of …
and internal organs, autoimmune abnormalities and widespread vasculopathy. A degree of …
Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy
Introduction: Interstitial lung disease (ILD) is the most serious complication of systemic
sclerosis (SSc). There is no accepted guidance as to which clinical, radiological or …
sclerosis (SSc). There is no accepted guidance as to which clinical, radiological or …
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials
Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …
Management of systemic sclerosis-associated interstitial lung disease
The specter of rapidly progressive lung disease requires clinicians to risk stratify patients
according to known predictors for progression and rigorously monitor for symptoms and …
according to known predictors for progression and rigorously monitor for symptoms and …
[HTML][HTML] Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies
Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc).
However, mortality is improving as pathogenesis is being better understood and new …
However, mortality is improving as pathogenesis is being better understood and new …
[HTML][HTML] Therapeutic options for systemic sclerosis related interstitial lung diseases
L Mouthon, A Bérezné, L Guillevin, D Valeyre - Respiratory medicine, 2010 - Elsevier
Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) mainly
encountered in patients with diffuse disease. Unlike idiopathic interstitial pneumonias (IIP) …
encountered in patients with diffuse disease. Unlike idiopathic interstitial pneumonias (IIP) …
Interstitial lung disease in systemic sclerosis: where do we stand?
S Cappelli, SB Randone, G Camiciottoli… - European …, 2015 - Eur Respiratory Soc
Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite
recent advances in the treatment is, at present, the major cause of death. Today, an early …
recent advances in the treatment is, at present, the major cause of death. Today, an early …